JP6131271B2 - カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法 - Google Patents

カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法 Download PDF

Info

Publication number
JP6131271B2
JP6131271B2 JP2014550770A JP2014550770A JP6131271B2 JP 6131271 B2 JP6131271 B2 JP 6131271B2 JP 2014550770 A JP2014550770 A JP 2014550770A JP 2014550770 A JP2014550770 A JP 2014550770A JP 6131271 B2 JP6131271 B2 JP 6131271B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
composition according
manganese
calmangafodipir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014550770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504066A (ja
JP2015504066A5 (index.php
Inventor
ヤン・オロフ・カールソン
カール・ライニキー
ティノ・クルツ
ロルフ・アンデション
マイケル・ホール
クリスティーナ・マクラフリン
スヴェン・ヤコブソン
ジャック・ネストレム
Original Assignee
プレッドファルマ・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレッドファルマ・アーベー filed Critical プレッドファルマ・アーベー
Publication of JP2015504066A publication Critical patent/JP2015504066A/ja
Publication of JP2015504066A5 publication Critical patent/JP2015504066A5/ja
Application granted granted Critical
Publication of JP6131271B2 publication Critical patent/JP6131271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014550770A 2012-01-05 2012-12-04 カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法 Active JP6131271B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261583377P 2012-01-05 2012-01-05
US61/583,377 2012-01-05
US201261656178P 2012-06-06 2012-06-06
US61/656,178 2012-06-06
US201261668679P 2012-07-06 2012-07-06
US61/668,679 2012-07-06
US201261721575P 2012-11-02 2012-11-02
US61/721,575 2012-11-02
PCT/IB2012/056959 WO2013102806A1 (en) 2012-01-05 2012-12-04 Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017081176A Division JP6316479B2 (ja) 2012-01-05 2017-04-17 カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法

Publications (3)

Publication Number Publication Date
JP2015504066A JP2015504066A (ja) 2015-02-05
JP2015504066A5 JP2015504066A5 (index.php) 2016-01-28
JP6131271B2 true JP6131271B2 (ja) 2017-05-17

Family

ID=47559596

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014550770A Active JP6131271B2 (ja) 2012-01-05 2012-12-04 カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法
JP2017081176A Active JP6316479B2 (ja) 2012-01-05 2017-04-17 カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017081176A Active JP6316479B2 (ja) 2012-01-05 2017-04-17 カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法

Country Status (15)

Country Link
US (3) US9187509B2 (index.php)
EP (1) EP2800755B1 (index.php)
JP (2) JP6131271B2 (index.php)
KR (1) KR102086022B1 (index.php)
CN (2) CN107353313B (index.php)
AU (1) AU2012364227B2 (index.php)
BR (1) BR112014016497B1 (index.php)
CA (1) CA2862736C (index.php)
ES (1) ES2683038T3 (index.php)
HK (1) HK1245276B (index.php)
IN (1) IN2014MN01495A (index.php)
MX (1) MX2014008247A (index.php)
RU (2) RU2622646C2 (index.php)
WO (1) WO2013102806A1 (index.php)
ZA (1) ZA201404904B (index.php)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022244757A1 (ja) 2021-05-18 2022-11-24 株式会社Ｌｔｔバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN01495A (index.php) * 2012-01-05 2015-04-17 Pledpharma Ab
US20150313921A1 (en) * 2012-11-02 2015-11-05 Pledpharma Ab Cancer Treatment Methods
US10233205B2 (en) 2015-08-07 2019-03-19 Auburn University Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species
EP3402475B1 (en) 2016-01-11 2021-10-20 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
JP7065866B2 (ja) * 2016-11-14 2022-05-12 カールソン－タナー インベスト エーエス 化学療法で誘発されたｐｓｎを防止および処置するための非遷移金属配位ジピリドキシル化合物の使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091169A (en) 1987-05-08 1992-02-25 Salutar, Inc. Dipyridoxyl phosphate NMRI contrast agent compositions
US5223243A (en) 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
AR246956A1 (es) 1987-05-08 1994-10-31 Salutar Inc Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste.
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
EP1060174B1 (en) 1997-12-23 2004-09-22 Amersham Health AS Nitric oxide releasing chelating agents and their therapeutic use
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
DE10359628A1 (de) 2003-12-18 2005-07-21 Oxeno Olefinchemie Gmbh Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
CA2708113C (en) 2007-12-14 2017-08-22 Pledpharma Ab Compounds for use in the treatment of cancer
US8414866B2 (en) * 2007-12-17 2013-04-09 Ge Healthcare As Method of magnetic resonance imaging of the heart with paramagnetic MN2+
MX336359B (es) * 2009-07-06 2016-01-15 Pledpharma Ab Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.
IN2014MN01495A (index.php) * 2012-01-05 2015-04-17 Pledpharma Ab

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022244757A1 (ja) 2021-05-18 2022-11-24 株式会社Ｌｔｔバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物
KR20240008844A (ko) 2021-05-18 2024-01-19 가부시키가이샤 엘티티 바이오파마 항암제의 투여에 수반되는 장애를 치료 또는 예방하기 위한 의약 조성물

Also Published As

Publication number Publication date
WO2013102806A1 (en) 2013-07-11
IN2014MN01495A (index.php) 2015-04-17
MX2014008247A (es) 2015-03-09
AU2012364227B2 (en) 2017-12-07
BR112014016497A8 (pt) 2017-07-04
CA2862736A1 (en) 2013-07-11
CN104169291B (zh) 2017-08-15
EP2800755A1 (en) 2014-11-12
JP6316479B2 (ja) 2018-04-25
HK1245276B (zh) 2020-05-08
CN107353313A (zh) 2017-11-17
BR112014016497B1 (pt) 2021-02-23
US20170165281A1 (en) 2017-06-15
EP2800755B1 (en) 2018-05-30
RU2622646C2 (ru) 2017-06-19
US20150005259A1 (en) 2015-01-01
JP2015504066A (ja) 2015-02-05
KR102086022B1 (ko) 2020-03-06
CN104169291A (zh) 2014-11-26
KR20140117480A (ko) 2014-10-07
JP2017132801A (ja) 2017-08-03
RU2765805C2 (ru) 2022-02-03
ES2683038T3 (es) 2018-09-24
US9597334B2 (en) 2017-03-21
CA2862736C (en) 2020-09-08
US9187509B2 (en) 2015-11-17
RU2014132184A (ru) 2016-02-27
HK1203203A1 (en) 2015-10-23
CN107353313B (zh) 2019-04-09
US10111893B2 (en) 2018-10-30
BR112014016497A2 (pt) 2017-06-13
US20160038507A1 (en) 2016-02-11
AU2012364227A1 (en) 2014-07-24
RU2017119660A (ru) 2018-11-08
RU2017119660A3 (index.php) 2020-07-30
ZA201404904B (en) 2024-01-31

Similar Documents

Publication Publication Date Title
JP6316479B2 (ja) カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法
HK1245276A1 (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
Karlsson et al. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct
US10688087B2 (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
HK1203203B (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
JP2007075058A (ja) 新規なカタラーゼ金属ポルフィリン錯体複合体、及びそれを含有してなる抗酸化組成物
Hussain et al. Therapeutic Potential of Rhodium Complexes
JP2019535823A (ja) 化学療法で誘発されたｐｓｎを防止および処置するための非遷移金属配位ジピリドキシル化合物の使用
COPPER II et al. DOUGLAS HIDEKI NAKAHATA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170417

R150 Certificate of patent or registration of utility model

Ref document number: 6131271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250